1. Increased expression of microRNA-155 in peripheral blood mononuclear cells from psoriasis patients is related to disease activity
- Author
-
European Commission, Agencia Estatal de Investigación (España), Junta de Andalucía, Ministerio de Ciencia, Innovación y Universidades (España), Rosal-Vela, Antonio [0000-0002-5256-6634], Sancho, Jaime [0000-0003-3852-7951], Zubiaur, Mercedes [0000-0002-4127-3027], García-Rodríguez, Sonia, Arias-Santiago, S., Blasco-Morente, G, Orgaz-Molina, J., Rosal-Vela, Antonio, Navarro, P., Magro-Checa, Cesar, Martinez-Lopez, A., Ruiz, J. C., Raya, Enrique, Naranjo-Sintes, R., Sancho, Jaime, Zubiaur, Mercedes, European Commission, Agencia Estatal de Investigación (España), Junta de Andalucía, Ministerio de Ciencia, Innovación y Universidades (España), Rosal-Vela, Antonio [0000-0002-5256-6634], Sancho, Jaime [0000-0003-3852-7951], Zubiaur, Mercedes [0000-0002-4127-3027], García-Rodríguez, Sonia, Arias-Santiago, S., Blasco-Morente, G, Orgaz-Molina, J., Rosal-Vela, Antonio, Navarro, P., Magro-Checa, Cesar, Martinez-Lopez, A., Ruiz, J. C., Raya, Enrique, Naranjo-Sintes, R., Sancho, Jaime, and Zubiaur, Mercedes
- Abstract
Background MicroRNAs (miRNAs) gene expression regulators are altered in psoriasis suggesting their role in the pathogenesis. Objective To study expression changes of inflammation and toll-like receptor (TLR)-related miRNAs, miRNA-155, let-7i, miRNA-21, miRNA-146a and miRNA-223 in peripheral mononuclear cells (PBMCs) and miRNA-21, miRNA-146a and miRNA-223 in plasma, from chronic plaque-type psoriasis patients who were treatment-naive or had undergone a washout period (n = 11). MiRNAs were evaluated at baseline and after 11 (9-12) months [median (25th-75th percentile range)] of methotrexate (MTX) or topical (betamethasone plus calcipotriene) treatment. Methods MiRNA expression was analysed with quantitative real-time reverse transcription-polymerase chain reaction. Matched controls were studied. Results Psoriasis patients presented, at baseline, increased expression of miRNA-155, let-7i, miRNA-146a, miRNA-21 and miRNA-223 in PBMCs, plus miRNA-21, miRNA-146a and miRNA-223 in plasma. Receiver-operator characteristic (ROC) curve analysis and area under the curve (AUC) showed that expression of these miRNAs have the potential to distinguish between psoriasis and controls. At baseline, miRNA-155 expression in PBMCs correlated with Psoriasis Area Severity Index (PASI) [12 (8-14)] (Spearman r: 0.7140, P < 0.05) suggesting a role in psoriasis. After MTX or topical treatment, reduction in PASI was observed [87.5% (75-100)]; miRNA-155 expression in PBMCs decreased; plasma miRNA-21, miRNA-146a and miRNA-223 were down-regulated. ROC analysis showed that miRNA-155 expression in PBMCs from psoriasis patients have the potential to distinguish between patients' samples at baseline and after treatment (AUC: 0.942, sensitivity: 0.91; specificity: 0.91 values; maximum likelihood ratio = 10). After treatment, miRNA-146a expression in PBMCs increased; miRNA-155/miRNA-146a ratio decreased, suggestive of a regulatory feedback; let-7i expression decreased; miRNA-21 and miRNA-223 remained ele
- Published
- 2017